Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies

Executive Summary

FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.

You may also be interested in...



FDA Officials Say Potency Problems Main Reason for NTI Drug Recalls

FDA officials said that use of quality by design as well as “equivalence by design” will help drug manufacturers develop better generic substitutions of narrow therapeutic index (NTI) drugs to address the high rate of recalls associated with these products due to potency problems.

FDA Officials Say Potency Problems Main Reason for NTI Drug Recalls

FDA officials said that use of quality by design as well as “equivalence by design” will help drug manufacturers develop better generic substitutions of narrow therapeutic index (NTI) drugs to address the high rate of recalls associated with these products due to potency problems.

Boosting Therapeutic Substitution Rests With Physician Education, HHS Says

Issue brief by the Office of the Assistant Secretary for Planning and Evaluation cites cost-savings potential of increasing substitution of brand drugs with generics that are not therapeutically equivalent but carry the same indication.

Related Content

Topics

UsernamePublicRestriction

Register

PS053662

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel